At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions.

We are expanding our commitment in cardiovascular disease (CVD), a disease that impacts millions of people worldwide.

25 мар. 2024 г. · Novo Nordisk is buying Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) as the Wegovy maker moves to strengthen its ...

25 мар. 2024 г. · “By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ...

25 мар. 2024 г. · “By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ...

25 мар. 2024 г. · Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) to strengthen ...

26 мар. 2024 г. · Novo Nordisk announced that it has acquired Cardior Pharmaceuticals in hopes of improving its pipeline in cardiovascular disease management.

25 мар. 2024 г. · Novo Nordisk has agreed to acquire Cardior for up to €1.025 billion ($1.11 billion), in a deal designed to enhance its cardiovascular drug pipeline with RNA- ...

25 мар. 2024 г. · Novo Nordisk has agreed to acquire Germany-based Cardior Pharmaceuticals for up to €1bn ($1.1bn) to expand its cardiovascular pipeline.

27 мар. 2024 г. · Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, ...